- Home
- FRPH vs VNDA Comparison
FRPH vs VNDA Comparison
Compare FRPH & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRPH | VNDA |
|---|---|---|
| Founded | 1986 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.3M | 441.5M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | FRPH | VNDA |
|---|---|---|
| Price | $23.86 | $8.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.63 |
| AVG Volume (30 Days) | 60.8K | ★ 2.8M |
| Earning Date | 03-04-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | $33,049,999.00 | ★ $212,074,000.00 |
| Revenue This Year | N/A | $12.01 |
| Revenue Next Year | N/A | $24.28 |
| P/E Ratio | $97.90 | ★ N/A |
| Revenue Growth | 5.21 | ★ 11.12 |
| 52 Week Low | $21.68 | $3.81 |
| 52 Week High | $31.99 | $9.60 |
Technical Indicators
Market Signals| Indicator | FRPH | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 61.30 |
| Support Level | $23.42 | $7.14 |
| Resistance Level | $24.62 | $7.82 |
| Average True Range (ATR) | 0.53 | 0.44 |
| MACD | 0.07 | -0.05 |
| Stochastic Oscillator | 61.14 | 62.09 |
Price Performance
Historical ComparisonAbout FRPH FRP Holdings Inc.
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.